We have 4 of 505 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
The findings identify the ESAM/Calnexin/mTOR axis as a candidate biomarker and therapeutic vulnerability in HER2-positive breast cancer and attenuates sensitivity to anti-HER2 therapy.
Objective Age-associated molecular heterogeneity is well described in female breast cancer but remains insufficiently characterized in male breast cancer (MBC). We profiled age-stratified clinical and molecular differences between younger (≤55 years) male breast cancer (YMBC) and older (>55 years) male breast cancer (O...
The results found that women diagnosed with FBC had an early onset of disease in the population studied, and the poor outcome of patients with a family history of BOC associated with survival was restricted to the hormone receptor-positive population.
The results of the present study suggest that ML can inhibit the proliferation and migration of BRCA cells whilst inducing their apoptosis by regulating the expression of key proteins.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
